Dr. Imus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
- Johns Hopkins UniversityFellowship, Medical Oncology, 2017 - 2019
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2011 - 2014
- Columbia University Vagelos College of Physicians and SurgeonsClass of 2011
Certifications & Licensure
- MD State Medical License 2014 - 2026
- VA State Medical License 2023 - 2026
- NC State Medical License 2020 - 2022
- NY State Medical License 2013 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Resiliency in Older Adults Undergoing Bone Marrow Transplant Start of enrollment: 2018 Sep 28
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis.Yosra M Aljawai, Hua-Ling Tsai, Ravi Varadhan, Richard J Jones, Philip H Imus
British Journal of Haematology. 2024-10-01 - 3 citationsRecipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies.Philip H Imus, Sergiu Pasca, Hua-Ling Tsai, Yosra M Aljawai, Kenneth R Cooke
Blood Advances. 2024-07-23 - 3 citationsA comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping.Ying S Zou, Melanie Klausner, Jen Ghabrial, Victoria Stinnett, Patty Long
Blood Cancer Journal. 2024-05-03
Abstracts/Posters
- Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 PatientsPhilip Hollingsworth Imus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- CD38 Knockout Primary NK Cells to Prevent Fratricide and Boost Daratumumab ActivityPhilip Hollingsworth Imus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: